Danaher Co. (NYSE:DHR) Shares Acquired by Bancreek Capital Management LP

Bancreek Capital Management LP increased its holdings in Danaher Co. (NYSE:DHR - Free Report) by 8.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,013 shares of the conglomerate's stock after acquiring an additional 4,746 shares during the period. Danaher comprises about 10.7% of Bancreek Capital Management LP's holdings, making the stock its 2nd largest holding. Bancreek Capital Management LP's holdings in Danaher were worth $16,963,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Dillon & Associates Inc. grew its stake in Danaher by 3.2% in the third quarter. Dillon & Associates Inc. now owns 49,740 shares of the conglomerate's stock valued at $13,828,000 after purchasing an additional 1,564 shares in the last quarter. Aptus Capital Advisors LLC increased its holdings in Danaher by 11.8% in the third quarter. Aptus Capital Advisors LLC now owns 6,516 shares of the conglomerate's stock worth $1,812,000 after buying an additional 689 shares during the last quarter. Aigen Investment Management LP bought a new position in Danaher during the third quarter valued at approximately $2,990,000. Hemenway Trust Co LLC increased its stake in shares of Danaher by 0.9% during the 3rd quarter. Hemenway Trust Co LLC now owns 156,379 shares of the conglomerate's stock worth $43,477,000 after purchasing an additional 1,438 shares during the last quarter. Finally, Savvy Advisors Inc. raised its holdings in shares of Danaher by 402.8% during the 3rd quarter. Savvy Advisors Inc. now owns 4,349 shares of the conglomerate's stock valued at $1,209,000 after purchasing an additional 3,484 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DHR. TD Cowen raised their price objective on Danaher from $310.00 to $315.00 and gave the company a "buy" rating in a research note on Wednesday, October 23rd. Robert W. Baird decreased their target price on Danaher from $278.00 to $277.00 and set an "outperform" rating on the stock in a report on Wednesday, October 23rd. UBS Group reduced their price target on shares of Danaher from $309.00 to $305.00 and set a "buy" rating on the stock in a research report on Wednesday, October 23rd. Bank of America raised their price objective on shares of Danaher from $270.00 to $275.00 and gave the company a "neutral" rating in a research report on Wednesday, July 24th. Finally, StockNews.com raised shares of Danaher from a "hold" rating to a "buy" rating in a research note on Wednesday, November 6th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $287.16.

Danaher Trading Up 0.5 %

DHR traded up $1.15 during mid-day trading on Wednesday, hitting $240.75. The stock had a trading volume of 1,001,949 shares, compared to its average volume of 2,740,845. The stock's fifty day simple moving average is $263.88 and its 200-day simple moving average is $260.77. The firm has a market capitalization of $173.89 billion, a price-to-earnings ratio of 46.08, a price-to-earnings-growth ratio of 4.40 and a beta of 0.85. Danaher Co. has a 1-year low of $200.36 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the business posted $2.02 EPS. The firm's revenue was up 3.1% compared to the same quarter last year. As a group, research analysts forecast that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher's dividend payout ratio (DPR) is currently 20.61%.

Insider Activity

In related news, SVP Georgeann Couchara sold 952 shares of the business's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company's stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.